… It has higher affinity for the AR than bicalutamide and has … trial of enzalutamide versus
bicalutamide in men with non-… -free survival compared to bicalutamide in both groups [22]. These …

… both prostate tumor cell lines and xenograft models. Moreover, AZD5363 in combination with
the antiandrogen bicalutamide … reduction in prostate tumor burden than everolimus in Pten-…

… cancer, and neuroendocrine pancreatic cancer (everolimus … significant effect so far in prostate
cancer patients92, 93, although … and bicalutamide for castration-resistant prostate cancer. …

… Additional clinical trials are underway in prostate cancer patients where apalutamide is
combined with GnRH ligands, abiraterone acetate, or the mTOR inhibitor everolimus. …

… Approximately 80% of patients diagnosed with PCa have prostate-limited localized PCa [2].
Localized PCa is a cancer that is inside the prostate gland and has not yet spread to other …

… The historical 6-month PFS survival rate was 24.5%, based on everolimus-treated patients
in men with metastatic chemorefractory CRPC [24] and data reported in the phase III TROPIC …

… bicalutamide is a CYP inducer in laboratory animals, dosages ≤150 mg/d have shown no
evidence of enzyme induction in humans.49, 50 Because bicalutamide … sirolimus, everolimus) …

… or everolimus 24,25 . Of these compounds, NVP-BEZ235 likely has the most promise, although
everolimus … xenografts, and interferes with self-renewal of bicalutamide resistant cells 91 . …

… and androgen-dependent gene transcription in prostate cancer cell lines overexpressing
AR and in contrast to the first-generation antiandrogen bicalutamide, it does not exhibit agonist …

… an eight-times higher affinity than bicalutamide and reduces the … In contrast to bicalutamide,
MDV3100 has no known agonist … Although, everolimus does not have clear significant single …